Document Detail


Diabetic macular edema: new trends in management.
MedLine Citation:
PMID:  22142159     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The treatment of diabetic macular edema may be evolving from a laser ablative approach into a pharmacotherapeutic approach. The exponential growth that has occurred over the past decade in the retinal pharmacotherapy field has led to the development of several pharmacotherapies for retinal vascular diseases such as diabetic macular edema. Many of these agents, in the form of intravitreal injections or sustained delivery devices, have already undergone clinical trial testing for safety and efficacy and many others are currently being similarly evaluated. Some of these agents have proven to be more efficacious than traditional laser therapy, and it is possible that traditional laser therapy for diabetic macular edema may be abandoned altogether in the near future, especially with the introduction of the micropulse laser. However, more research and experience is still needed in order to determine the best treatment agent or combination of therapeutic modalities, as well as the best treatment regimen for a given patient. In this article, we briefly review the major new developments in the field of diabetic macular edema treatment. In addition, we touch on some of the promising forthcoming therapies.
Authors:
Hanan Al Shamsi; Nicola G Ghazi
Related Documents :
2723509 - Correlation of follicular diameter with oocyte recovery and maturity at the time of tra...
348539 - Heterogeneity in diabetes mellitus--update, 1978. evidence for further genetic heteroge...
22020349 - Polymorphisms of insig2, mc4r, and lep are associated with obesity- and metabolic-relat...
268169 - Lack of relationship between viruses and human diabetes mellitus.
388999 - Diabetes mellitus challenges for the future.
21116029 - Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is ass...
15547649 - The levels of soluble adhesion molecules in diabetic and nondiabetic patients with comb...
10525659 - Antibodies to tissue transglutaminase c in type i diabetes.
12743229 - Impaired insulin sensitivity among nondiabetic patients with a recent tia or ischemic s...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of clinical pharmacology     Volume:  5     ISSN:  1751-2441     ISO Abbreviation:  Expert Rev Clin Pharmacol     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278296     Medline TA:  Expert Rev Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  55-68     Citation Subset:  IM    
Affiliation:
Vitroretinal Division, King Khaled Eye Specialist Hospital, PO Box 7191, Riyadh 11462, Saudi Arabia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?
Next Document:  Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic ...